Abstract: A particulate matter sensor system for sensing particulate matter in a fluid includes a substrate and a cover disposed on the substrate. The cover defines at least a portion of a flow path through the microfluidic system. The sensor system includes a particulate matter sensor disposed in an interior space between the cover and the substrate. The particulate matter sensor includes an integrated sensor device electrically connected to the substrate. The flow path is defined through the particulate matter sensor. The sensor system includes a fluid circulation device disposed in the interior space between the cover and the substrate and configured to cause fluid to flow along the flow path through the microfluidic system.

Abstract: The present invention relates to novel inhibitors of adipose triglyceride lipase (ATGL) having an improved inhibitory activity against human ATGL (hATGL) as well as pharmaceutical compositions comprising these inhibitors, and their therapeutic use, particularly in the treatment or prevention of a lipid metabolism disorder, including, e.g., obesity, non-alcoholic fatty liver disease, type 2 diabetes, insulin resistance, glucose intolerance, hypertriglyceridemia, metabolic syndrome, cardiac and skeletal muscle steatosis, congenital generalized lipodystrophy, familial partial lipodystrophy, acquired lipodystrophy syndrome, atherosclerosis, or heart failure.

Abstract: An electrode for an electrochemical element with an organic electrolyte includes a polymeric material containing or composed of subunits according to general formulae (I) and/or (II): wherein n is an integer ?2, Y represents an amide group (—NH—CO— or —CO—NH—), an ester group (—O—CO— or —CO—O—) or a urethane group (—NH—CO—O— or —O—CO—NH—), R1, R2, R3 and R4 each independently represent H, alkyl (preferably —CH3, —C2H5), Alkoxy-(preferably —OCH3, —OC2H5), -halogen or —CN, Ar1 and Ar4 independently represent a bridging aryl group, Ar2 and Ar3 independently represent a non-bridging aryl group, and R5 is a bridging alkyl, alkene or aryl group, wherein Ar1 and Ar4 in structures (I) and (II) independently represent a bridging aryl group.

Abstract: A method a described which includes depositing a first component of a multicomponent system by means of an inkjet process, and depositing a second component of the multicomponent system by means of an inkjet process.

Abstract: An electronic device includes a synchronous rectification circuit having an actively controlled switching element through which resonant current flows during operation. The actively controlled switching element is disposed in a package which adds stray inductance to a main current path of the synchronous rectification circuit. The electronic device also includes a fixed inductor magnetically coupled to the stray inductance or an additional inductance in series with the stray inductance so that the fixed inductor is not in the main current path of the synchronous rectification circuit and change in current through the inductance to which the fixed inductor is magnetically coupled induces a reference voltage at the fixed inductor which is in phase with a zero crossing point of the resonant current at different switching frequencies of the actively controlled switching element. A corresponding method of controlling the electronic device is also described.

Abstract: A compound of formula (I) as defined herein is useful in the treatment and prevention of a disorder such as cachexia, stroke, atherosclerosis, coronary artery disease, and diabetes and pharmaceutical compositions of the same. Also, a method of screening for lipase inhibitors using a compound of formula (I) and determining its lipase inhibitory activity. The method includes in vitro assays of compounds using ATGL and/or HSL, and cellular assays wherein inhibition is followed by observing indicators of efficacy. Also, methods for treatment or prevention of a condition involving cachexia, stroke, artherosclerosis, coronary artery disease, diabetes, preferably diabetes type II by administering a pharmaceutical composition comprising an agent which is able to inhibit ATGL. Also contemplated herein, are compositions comprising one or more ATGL-inhibiting agents optionally in combination with one or more lipase inhibitors or inhibitors of inflammatory cytokines.

Abstract: Method for compensating illumination deficiencies in microscopic “shape from focus (SFF)”, wherein firstly the reflectance of the scene is estimated by way of a projector-camera system and then microscopic “shape from focus (SFF)” is applied to a stack of reflectance maps rather than to the original image data.

Abstract: A mutant Pichia pastoris alcohol oxidase 1 (AOX1) promoter of the wild type Pichia pastoris AOX1 promoter (SEQ ID No. 1) comprising at least one mutation selected from the group consisting of: a) a transcription factor binding site (TFBS), b) nucleotides 170 to 235 (?784 to ?719), nucleotides 170 to 191 (?784 to ?763), nucleotides 192 to 213 (?762 to ?741), nucleotides 192 to 210 (?762 to ?744), nucleotides 207 to 209 (?747 to ?745), nucleotides 214 to 235 (?740 to ?719), nucleotides 304 to 350 (?650 to ?604), nucleotides 364 to 393 (?590 to ?561), nucleotides 434 to 508 (?520 to ?446), nucleotides 509 to 551 (?445 to ?403), nucleotides 552 to 560 (?402 to ?394), nucleotides 585 to 617 (?369 to ?337), nucleotides 621 to 660 (?333 to ?294), nucleotides 625 to 683 (?329 to ?271), nucleotides 736 to 741 (?218 to ?213), nucleotides 737 to 738 (?217 to ?216), nucleotides 726 to 755 (?228 to ?199), nucleotides 784 to 800 (?170 to ?154) or nucleotides 823 to 861 (?131 to ?93) of Seq ID No.

Abstract: The present invention relates to pre-catalysts for olefin metathesis and composition involving these pre-catalysts.

Abstract: The present invention relates to a novel polymeric material with enhanced hydrophilicity for medical use comprising a biocompatible polyester material selected from the group consisting of poly(hydroxyalkanoate)s, poly(lactic acid)s, poly(glycolic acid)s, poly(caprolactone)s and copolymers and blends thereof, wherein the biocompatible polyester material is crosslinked with a functionalized poly(alkylene oxide) having at least two functional groups independently selected from the group consisting of azido-formate and alkanoyl azide. The novel polymeric material with enhanced hydrophilicity is useful as a biocompatible material in a variety of medical applications, including medical implants, bioresorbable implants, tissue engineering, and controlled release.

Abstract: The present invention relates to a novel polymeric material with enhanced hydrophilicity for medical use comprising a biocompatible polyester material selected from the group consisting of poly(hydroxyalkanoate)s, poly(lactic acid)s, poly(glycolic acid)s, poly(caprolactone)s and copolymers and blends thereof, wherein the biocompatible polyester material is crosslinked with a functionalized poly(alkylene oxide) having at least two functional groups independently selected from the group consisting of azido-formate and alkanoyl azide. The novel polymeric material with enhanced hydrophilicity is useful as a biocompatible material in a variety of medical applications, including medical implants, bioresorbable implants, tissue engineering, and controlled release.

Abstract: The present invention relates to pre-catalysts for olefin metathesis and composition involving these pre-catalysts.

Abstract: A compound of formula (I) as defined herein is useful in the treatment and prevention of a disorder such as cachexia, stroke, atherosclerosis, coronary artery disease, and diabetes and pharmaceutical compositions of the same. Also, a method of screening for lipase inhibitors using a compound of formula (I) and determining its lipase inhibitory activity. The method includes in vitro assays of compounds using ATGL and/or HSL, and cellular assays wherein inhibition is followed by observing indicators of efficacy. Also, methods for treatment or prevention of a condition involving cachexia, stroke, artherosclerosis, coronary artery disease, diabetes, preferably diabetes type II by administering a pharmaceutical composition comprising an agent which is able to inhibit ATGL. Also contemplated herein, are compositions comprising one or more ATGL-inhibiting agents optionally in combination with one or more lipase inhibitors or inhibitors of inflammatory cytokines.

Abstract: A sensor system is located in an environment composed of a first medium, where waves propagate with a first phase velocity, the sensor system including at least one main enclosure and a sensor array with at least two sensors, said sensor array being arranged inside the main enclosure, wherein the space inside the main enclosure between the sensor array and the inner surface of the main enclosure is filled with a second medium, in which waves propagate with a second phase velocity, the second phase velocity being different from the first velocity.

Abstract: Described herein is a method for detecting a wound infection comprising the steps of: contacting a sample obtained from a wound with at least two substrates for at least two enzymes selected from the group consisting of lysozyme, elastase, cathepsin G and myeloperoxidase, and detecting a wound infection when a conversion of the at least two substrates with said at least two enzymes are determined.

Abstract: The present invention relates to a method for detecting a wound infection comprising the steps of: contacting a sample obtained from a wound with at least two substrates for at least two enzymes selected from the group consisting of lysozyme, elastase, cathepsin G and myeloperoxidase, and detecting a wound infection when a conversion of the at least two substrates with said at least two enzymes are determined.

Abstract: The invention relates to a method for localizing and tracking acoustic sources (101) in a multi-source environment, comprising the steps of recording audio-signals (103) of at least one acoustic source (101) with at least two recording means (104, 105), creating a two- or multi-channel recording signal, partitioning said recording signal into frames of predefined length (N), calculating for each frame a cross-correlation function as a function of discrete time-lag values (?) for channel pairs (106, 107) of the recording signal, evaluating the cross-correlation function by calculating a sampling function depending on a pitch parameter (f0) and at least one spatial parameter (?0), the sampling function assigning a value to every point of a multidimensional space being spanned by the pitch-parameter and the spatial parameters, and identifying peaks in said multidimensional space with respective acoustic sources in the multi-source environment.

Abstract: A receiver device for detecting a multi-band signal, the receiver device comprising a bank of autocorrelation units adapted for separating the multi-band signal into a set of autocorrelation signals, and a sampling stage arranged downstream the bank of autocorrelation units and adapted for sampling the set of autocorrelation signals to thereby select individual signal components for detection.

Abstract: A method and an apparatus for magnetic induction tomography, in which an object with inhomogeneous passive electrical properties is exposed to an alternating magnetic field by excitation coils located at different positions, from which receiver coils located at different positions pick up AC signals which contain information concerning the electrical conductivity and its distribution in the object, and images of the spatial electrical properties in the interior of the object are reconstructed from the amplitudes and phases of the received signals, whereas the measurement is carried out at least 2 frequencies and an additional perturbation of the coils and/or the field geometry so as to determine a correction factor with which it is possible to widely eliminate spurious signals generated by changes of the geometry during the object measurement.

Abstract: A method and system for recovering useful information, in particular useful information transmitted in digital form on terrestrial or satellite-based information paths, for example as voice, image or data signal, from channel-coded data streams encoded with turbo codes with a predefined code rate is disclosed. The data streams are received by a turbo decoder with a presettable number of decoder components and subsequently decoded in an iterative process according to the MAP and/or Max-Log-MAP standard. The iterative process is controlled by a stop criterion, wherein after termination of the iterative process in the turbo decoder at least one of the decoder components, in particular the associated lattice diagram, is used for an additional decoding process that is different from the MAP and/or Max-Log-MAP standard. This approach lowers the error floor of the turbo code.